Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,447 signal articles · 142 in last 24h · 154,069 total before filter · latest 50m ago
142last 24h
875last 7d
146● bullish (7d)
99● bearish (7d)
214publishers
AllMacro207Earnings108M&A125Regulatory22Product21Analyst17
✕ clear all filtersticker: AXPSentiment:bullishneutralbearishshow all (incl. clickbait)
EXCLUSIVE: Ticketplus Buys Argentina's Autoentrada as Post-IPO Expansion Strategy Takes Shape
Benzinga3d agobullish
EXCLUSIVE: Ticketplus Buys Argentina's Autoentrada as Post-IPO Expansion Strategy Takes Shape

Ticketplus Ltd. (AMEX:TP), a Latin American (Santiago, Chile-based) live-entertainment technology company, acquired Argentine ticketing company Autoentrada S.A., marking its first acquisition since its August 2026 IPO. Autoentrada Adds Scale And Local Leaderships The deal converts Autoentrada from a Ticketplus white-label partner into a full operation in Argentina, giving Ticketplus direct relationships with promoters and greater control over sales, payments, access, and analytics. The financial

SRX Global Acquires Stake in Vistagen Therapeutics
InvestorsHub51d agoneutral
SRX Global Acquires Stake in Vistagen Therapeutics

SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. Key Investor TakeawaysSRX Global (AMEX:SRXH) acquired a stake in Vistagen Therapeutics (NASDAQ:VTGN).